RECURSION PHARMACEUTICALS, INC. (RXRX) research
RECURSION PHARMACEUTICALS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.70
- As of
RECURSION PHARMACEUTICALS, INC. (RXRX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-21.
As of . Source: SEC EDGAR filings for RXRX. Method and limitations.
Share the RXRX intelligence card
See RXRX live in the terminal
Track RXRX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live RXRX terminal, freeActive signals for RXRX
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 93% of RXRX (2026Q2)
- mediumNEW_POSITION
Bridgewater Associates, LP new position in RXRX
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 93% of RXRX (2026Q2)
- mediumNEW_POSITION
Bridgewater Associates, LP new position in RXRX
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 93% of RXRX (2026Q2)
FREE, NO ACCOUNT
Every signal on RXRX, as it fires
You are seeing 5 of 12 signals recorded on RXRX since 2026-06-05.
The five above landed across 2 days. The other 7 were recorded on 2 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RXRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 75629V104 · 2026Q2 | $12.3M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 75629V104 · 2026Q2 | $6.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 75629V104 · 2026Q2 | $472K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 75629V104 · 2026Q2 | $139K | 0.00% | , |
| Bridgewater Associates, LPCUSIP 75629V104 · 2026Q2 | $138K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RXRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
RXRX against its peers
RXRX's operating margin of -867.9% ranks in the 26th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | RXRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 74.7M USD | 68.6M USD | 53 | 15 |
| Operating margin | -867.9% | -145.0% | 26 | 16 |
| Net margin | -863.4% | -106.4% | 19 | 17 |
| Return on equity | -57.0% | -35.1% | 36 | 20 |
Peers (22): NBTX, TSHA, IMCR, NVAX, TYRA, NTLA, FBRX, ANAB, LKFT, SEPN, SNDX, BHVN, STOK, INBX, ABSI, ZYME, XNCR, GHRS, VIR, BCAX, MESO, AGIO. Left out: KLRA (no annual filing), KARD (no annual filing), COAG (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (RXRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RXRX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RXRXand get the insider, 13F, options, and confluence read in one view.